Regenxbio
RGNX on Nasdaq. REGENXBIO licenses gene therapy technology to drugmakers and develops treatments for patients. Market value $512m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
Capital spending looks too small to be complete, so we leave free cash flow out.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 34 of 100. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$7.45 a share, 37% above its 1-year low
Over the past year the price has ranged from $5.45 to $16.19.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $470m | $113m | $90m | $83m | $170m |
| Operating margin | |||||
| Operating margin | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.05bn | 0.05bn | 0.07bn |
Health checks
- Free cash flow positive1 of 3 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)2 of 7 checks we could run
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsSlow, 2.0% a year
- Buying back its own sharesNo, 52% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $108 million last quarter, up 406% on a year ago.
- Profit: $23 million, after a loss of $71 million a year ago.
- It loses 94 cents on each $1 of sales, compared with 106 cents a year earlier.
- 3% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $24m |
| December 2024 | $21m |
| March 2025 | $89m |
| June 2025 | $21m |
| September 2025 | $30m |
| December 2025 | $30m |
| March 2026 | $6m |
| June 2026 | $108m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$60m |
| December 2024 | -$51m |
| March 2025 | $6m |
| June 2025 | -$71m |
| September 2025 | -$62m |
| December 2025 | -$67m |
| March 2026 | -$90m |
| June 2026 | $23m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 5 March 2026
- Next quarterly (estimated, 10-Q)
- 5 November 2026
Who owns it
None of the long-term investors we follow own it. 165 funds in all.
Sold out this quarter
- Voss CapitalTravis CockeSold out
Largest holders overall
- BlackRock$77mAdded
- Redmile Group$52m
- State Street$36mAdded
- JPMorgan Chase$26mCut
- Vanguard Capital Management$25mAdded
- Morgan Stanley$23mCut
- Goldman Sachs Group$17mCut
- AQR Capital Management$17mAdded
- Vanguard Portfolio Management$16mAdded
- Marshall Wace, LLP$15mNew
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- Redmile Group, LLCPassive investorat least 9.9%(filed with 2 related holders)Since 30 June 2025
- BlackRock, Inc.Passive investor7.3%−3.7 ptsSince 31 March 2025
- STATE STREET CORPORATIONPassive investor5.3%+0.9 ptsSince 31 March 2026
- JPMORGAN CHASE & COPassive investorSold down below 5%Since 29 May 2026
- BlackRock Portfolio Management LLCPassive investorSold down below 5%Since 31 December 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Redmile Group, LLC Passive investor | at least 9.9% (filed with 2 related holders) | 30 June 2025 | |
BlackRock, Inc. Passive investor | 7.3%−3.7 pts | 31 March 2025 | |
STATE STREET CORPORATION Passive investor | 5.3%+0.9 pts | 31 March 2026 | |
JPMORGAN CHASE & CO Passive investor | Sold down below 5% | 29 May 2026 | |
BlackRock Portfolio Management LLC Passive investor | Sold down below 5% | 31 December 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $949,381 of shares on the open market. 2 sold $1m, $513,849 of it under preset trading plans.
- Ciongoli Gregory AustinDirectorBought
- Date
- 27 August 2026
- Shares
- 53,407
- Price
- $9.36
- Value
- $499,676
- Ciongoli Gregory AustinDirectorBought
- Date
- 26 August 2026
- Shares
- 49,196
- Price
- $9.14
- Value
- $449,706
- PAKOLA STEVEChief Medical OfficerSoldunder a preset trading plan
- Date
- 2 July 2026
- Shares
- 2,161
- Price
- $13.64
- Value
- $29,476
- PAKOLA STEVEChief Medical OfficerSold
- Date
- 1 July 2026
- Shares
- 36,725
- Price
- $12.86
- Value
- $472,284
- PAKOLA STEVEChief Medical OfficerSold
- Date
- 29 June 2026
- Shares
- 19,608
- Price
- $11.04
- Value
- $216,472
- PAKOLA STEVEChief Medical OfficerSoldunder a preset trading plan
- Date
- 11 May 2026
- Shares
- 15,309
- Price
- $11.02
- Value
- $168,705
- PAKOLA STEVEChief Medical OfficerSoldunder a preset trading plan
- Date
- 10 March 2026
- Shares
- 5,124
- Price
- $10.35
- Value
- $53,033
- Simpson CurranChief Executive Officer, DirectorSoldunder a preset trading plan
- Date
- 9 October 2025
- Shares
- 20,811
- Price
- $12.62
- Value
- $262,635
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 27 August 2026 | Ciongoli Gregory Austin Director | Bought | 53,407 | $9.36 | $499,676 |
| 26 August 2026 | Ciongoli Gregory Austin Director | Bought | 49,196 | $9.14 | $449,706 |
| 2 July 2026 | PAKOLA STEVE Chief Medical Officer | Sold under a preset trading plan | 2,161 | $13.64 | $29,476 |
| 1 July 2026 | PAKOLA STEVE Chief Medical Officer | Sold | 36,725 | $12.86 | $472,284 |
| 29 June 2026 | PAKOLA STEVE Chief Medical Officer | Sold | 19,608 | $11.04 | $216,472 |
| 11 May 2026 | PAKOLA STEVE Chief Medical Officer | Sold under a preset trading plan | 15,309 | $11.02 | $168,705 |
| 10 March 2026 | PAKOLA STEVE Chief Medical Officer | Sold under a preset trading plan | 5,124 | $10.35 | $53,033 |
| 9 October 2025 | Simpson Curran Chief Executive Officer, Director | Sold under a preset trading plan | 20,811 | $12.62 | $262,635 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
- Sales have barely grown: 2.0% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.